TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: single sural nerve stimulation pain tolerance threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cold pressor pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of detected infringements for eligibility criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of major dose violations
Endpoint domain: Adverse events/effects
Primary endpoint: Positive patch test for wheat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Specificity of patch test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean survival of patients receiving TACE
Endpoint domain: Mortality/survival
Primary endpoint: Change in esodeviation at near distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in esodeviation at distant target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk distance (6MWD) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in inflammatory mediators (IL-8, TNF-α, LTB4, CRP, IL-17A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain response on visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum phospholipid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of disability in MS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite event of death, myocardial infarction, and revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Signs of phototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Signs of irritation
Endpoint domain: Adverse events/effects
Primary endpoint: ALT levels after 24 h and 48 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: AST levels after 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Duration of exercise at 70% peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma glycine maximal concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of glycine absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dressing-related concerns
Endpoint domain: Adverse events/effects
Primary endpoint: Incident chlamydial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incident gonococcal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of condom-protected sexual acts
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: C(max) - maximum plasma epinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t(max) - time of maximum plasma epinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of standardized measures for pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete protection from nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in papilloma growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of renal replacement function (RRF) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Alleviation of urges to smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desire for cigarettes within 10 min of use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehospitalizations in the first year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total unexpected postoperative visits (UPOVs)
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal haze formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lifetime diagnoses of alcohol use disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 Mental scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infarct-related artery patency at 90 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global ejection fraction at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional wall motion at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interobserver variability for prostate contouring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric distortion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-of-treatment drinking quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot flash intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Q.A.L.Y. gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nondense volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CNS infections
Endpoint domain: Adverse events/effects
Primary endpoint: Retention of fish selenium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apparent absorption of selenium from fish
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean reduction in surface area affected by eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: severity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcomes at 2 years postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of re-rupture
Endpoint domain: Adverse events/effects
Primary endpoint: diaphragm mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coping skills improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subcutaneous tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PU stage II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of onset of PU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oLAB titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correct classification of cognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative predictive value of TCAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive predictive value of TCAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prescribing of bisphosphonates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median survival from registration
Endpoint domain: Mortality/survival
Primary endpoint: Total resection rate of functional pituitary adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intravaginal cleansing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itching in the genital area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incomplete abortion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: continued pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Risk of SLTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admission in the last year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Inappropriate use of oral corticosteroids during acute attack
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of EIW
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall survival rates at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: mean PIPP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healed ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HbA1c at 5 years post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight retention at 5 years post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate and severe ovarian hyperstimulation syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: required dose of ephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to achieve maximal sensory block level (MSBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD64 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of CD64 expression to diagnose systemic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of CD64 expression to diagnose systemic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-GM1 and anti-GD1a titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: satisfactory sedation at separation from parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Actuarial incidence of at least CTC 2 radiation induced diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: responder rates for global IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: severity scores of abdominal pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: overall target plaque severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACh-induced skin perfusion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaque accumulation at occlusal surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: QTcH change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HR change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of atopic dermatitis (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in plaque volume and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: RV long-axis shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV long-axis shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of ability of daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: GLA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: emotion‐oriented coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lips volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin sagging of the face contours decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cured or completed treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of homosexual and bisexual sexual identity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of condom use
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Residual neurologic sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DNP severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma N-BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxford Knee Score (OKS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary outcome occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need for rescue medication
Endpoint domain: Adverse events/effects
Primary endpoint: nausea or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of staining method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distinguishing between used and unused applicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in best spectacle-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in National Eye Institute Visual Functioning Questionnaire-25 composite score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' skills level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fall rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural stability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limitations of Daily Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incontinence Impact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events/intolerability
Endpoint domain: Adverse events/effects
Primary endpoint: anxiety-depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: paid working life
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean serum albumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ulcer volume after 28 days of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Tactile Threshold (TT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in Pain Threshold (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tooth-whitening achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cross-neutralizing antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drug-free remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean DAS at restart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological progression
Endpoint domain: Adverse events/effects
Primary endpoint: free from local failure rate at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: radiation-induced damage to the central nervous system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Polysomnographic determinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit from tamoxifen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis on long-term follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage circumferential enhancement around the pulmonary vein antra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of procedures performed to achieve success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: near-normoglycemia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to achieve euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of switch to two-person CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence rate of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dry weight standard‐reaching rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average VAS pain at 1 hour after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doses of morphine usage for controlling postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean process composite improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuity of care rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ability to improve vascular health rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C(max) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: t(max) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiorespiratory fitness (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global Assessment of Function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sleep assessment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Minimal core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sebum and pore scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in average size of facial pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in dermal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacotherapy outcome expectancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prolonged drains output ≥ 15 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology life quality index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death during ART
Endpoint domain: Mortality/survival
Primary endpoint: Tuberculosis during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean time for skin closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average cost per closure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of abrupt vessel closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of ischemic events at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative oliguria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvements in daily activities (AMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb function (AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional tests of lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional neurological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes